Schiffmann Jonas, Haese Alexander, Lenz Jochen, Heinzer Hans, Salomon Georg, Steuber Thomas, Beyer Burkhard, Boehm Katharina, Tilki Derya, Michl Uwe, Tennstedt Pierre, Huland Hartwig, Graefen Markus, Karakiewicz Pierre I
Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Urol Int. 2016;97(1):8-15. doi: 10.1159/000443701. Epub 2016 Jan 19.
To examine the characteristics of robot-assisted radical prostatectomy (RARP) and open radical prostatectomy (ORP) patients at a high-volume center.
We relied on the Martini-Clinic database and focused on prostate cancer patients treated in 2013. Characteristics in ORP and RARP patients were assessed. In multivariable logistic regression analyses (MVA), we predicted RARP treatment.
Of 1,920 patients, 575 (29.9%) underwent RARP and 1,345 (70.1%) ORP. RARP patients had a lower prostate-specific antigen (PSA), and were less likely to harbor pT3b, pathological Gleason ≥4 + 4 or lymph node metastases (all p < 0.05). Pelvic lymph node dissection (PLND) (84.3 vs. 87.0%, p = 0.1), as well as positive surgical margins (15.5 vs. 15.7%, p = 0.7) and the nerve-sparing status (p = 0.5) were comparable between RARP and ORP. Lymph node yield (median 11 vs. 16), and median blood loss (250 vs. 700 ml) were lower at RARP (all p < 0.001). Additionally, the median operating room time was higher at RARP (215 vs. 185 min, p < 0.001). In MVA, patients with body mass index (BMI) ≥30 were more likely to undergo RARP (OR 1.8, 95% CI 1.3-2.4, p < 0.001). Conversely, patients with PSA >20 ng/ml were less likely to undergo RARP (OR 0.6, 95% CI 0.4-1.0, p = 0.03).
More favorable pathological characteristics were recorded at RARP. High BMI and low PSA were independent predictors for RARP. Treatment characteristics such as PLND rates, margin status and nerve sparing were comparable between RARP and ORP. Despite lower blood loss at RARP, a longer operating room time and lower yield of lymph nodes were recorded.
在一家大型医疗中心研究机器人辅助根治性前列腺切除术(RARP)和开放性根治性前列腺切除术(ORP)患者的特征。
我们依据马丁尼诊所数据库,重点关注2013年接受治疗的前列腺癌患者。对ORP和RARP患者的特征进行评估。在多变量逻辑回归分析(MVA)中,我们预测RARP治疗情况。
1920例患者中,575例(29.9%)接受了RARP,1345例(70.1%)接受了ORP。RARP患者的前列腺特异性抗原(PSA)较低,且患pT3b、病理Gleason评分≥4 + 4或淋巴结转移的可能性较小(所有p < 0.05)。盆腔淋巴结清扫术(PLND)(84.3%对87.0%,p = 0.1)、手术切缘阳性率(15.5%对15.7%,p = 0.7)以及保留神经情况(p = 0.5)在RARP和ORP之间具有可比性。RARP的淋巴结获取数量(中位数11对16)和中位失血量(250对700 ml)较低(所有p < 0.001)。此外,RARP的中位手术时间较长(215对185分钟,p < 0.001)。在MVA中,体重指数(BMI)≥30的患者更有可能接受RARP(比值比1.8,95%置信区间1.3 - 2.4,p < 0.001)。相反,PSA >20 ng/ml的患者接受RARP的可能性较小(比值比0.6,95%置信区间0.4 - 1.0,p = 0.03)。
RARP记录到更有利的病理特征。高BMI和低PSA是RARP的独立预测因素。RARP和ORP在PLND率、切缘状态和保留神经等治疗特征方面具有可比性。尽管RARP的失血量较少,但记录到手术时间较长且淋巴结获取数量较少。